FUT8 and prostate carcinoma: Our study provides proof‐of principle data to show metabolic inhibitors of fucosylation can be used to target FUT8‐mediated core fucosylation to reduce prostate cancer cell growth and highlights the potential to utilise these type of inhibitors as new therapies for prostate cancer.